Novartis' Cosentyx beats UCB drug to finish line as first new biologic for lesser-known skin condition in years

01 Nov 2023
www.fiercepharma.com
Drug Approval
Novartis' Cosentyx beats UCB drug to finish line as first new biologic for lesser-known skin condition in years
Preview
Source: FiercePharma
Novartis is counting on Cosentyx's approval in hidradenitis suppurativa and other new uses to drive the med's next phase of growth.
Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start.
That’s good news for the Swiss Pharma, given that dermatology experts predict UCB’s bimekizumab—also angling for an HS nod and recently approved in plaque psoriasis as Bimzelx—to be a strong rival in this disease area.
Late Tuesday, Novartis said the FDA approved Cosentyx (secukinumab) for the treatment of moderate to severe HS in adults. The green light makes Cosentyx the first new biologic to treat the lesser-known skin affliction in nearly a decade, Novartis said in a release.
HS is a painful skin disease for which, until now, only a single biologic treatment was available in the U.S.: AbbVie’s off-patent Humira.
The disease is associated with painful, boil-like abscesses that can turn into open wounds. HS is estimated to affect about 1 in 100 people globally, but, because of relatively low disease awareness among non-dermatologists, only about half of HS patients are diagnosed, a pair of dermatologist opinion leaders wrote in April, as quoted by analysts at SVB Securities.
The FDA approved Cosentyx based on data from Novartis’ late-stage SUNSHINE and SUNRISE studies. In the trials, Cosentyx helped more patients achieve lesion reduction versus placebo.
Cosentyx has been approved for HS as a 300-mg dose given every four weeks. Patients also have the option to transition to a biweekly dosing schedule if their response is inadequate.
Novartis has been banking on Cosentyx’s HS approval, along with potential new indications in giant cell arteritis and lupus nephritis, to drive the med’s next phase of growth. If all three indications are successful, Cosentyx could bring in an additional $2 billion in peak sales, Novartis has said.
In the third quarter, Cosentyx pulled down about $1.3 billion, growing 4% over the $1.27 billion it scored over the same stretch in 2022. For the first nine months of 2023, CosentyxCosentyx has generated a total of $3.7 billion.
While Novartis’ approval has given Cosentyx some space to breathe in HS, the drug may soon have a strong rival in UCB’s bimekizumab, which earlier this year posted data that were “incrementally better than” Cosentyx, according to an SVB note from April.
In data shared the American Academy of Dermatology’s annual meeting, bimekizumab significantly topped placebo on the proportion of patients who achieved at least 50% reduction of inflammatory lesions.
Despite recently winning a psoriasis nod as Bimzelx, bimekizumab hasn’t had an easy path to the regulatory finish line. While UCB had previously hoped an FDA decision in HS could come in 2023’s third quarter, the company in September said the agency was “continuing its review,” without providing more details.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.